Drug intelligence / Profile preview

AMG 513

Development stage: Phase 1
Lead developer: Amgen
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

AMG 513 is an investigational drug being developed by Amgen for the treatment of obesity. The mechanism of action is currently undefined or not publicly disclosed. The drug was being evaluated in a Phase 1 single and multiple ascending dose study to assess its safety and tolerability. As of February 2025, the clinical trial was placed on hold by the FDA, though Amgen has indicated they still expect to move forward with the candidate and don't believe the issue is related to the drug itself. The drug can be administered via subcutaneous or intravenous routes.

Beyond the preview

Go deeper on AMG 513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 513.

Explore the full profile